Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

Technology Transfer from the Weizmann Institute of ScienceTechnology Transfer from the Weizmann Institute of Science

f r o m o u r p i p e l i n e t o y o u r b o t t o m l i n ef r o m o u r p i p e l i n e t o y o u r b o t t o m l i n e

Amir Naiberg, CEOAmir Naiberg, CEO

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

Yeda’s Business Club- June 2013Yeda’s Business Club- June 2013

Science for the Benefit ofSociety

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

April 2013April 2013

Merieux announces:a two years collaboration with Prof. Ada Yonath. Merieux announces:a two years collaboration with Prof. Ada Yonath.

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

May 2013May 2013

Helio Focus announced that it signed a second strategic agreement with China Guodian Corporation, one of China’s largest power generation companies. The first stage of the agreement calls for HelioFocus to plan and develop a power boosting capability for Guodian’s 15MW – 40MW coal powered facility to be located in China.

Helio Focus announced that it signed a second strategic agreement with China Guodian Corporation, one of China’s largest power generation companies. The first stage of the agreement calls for HelioFocus to plan and develop a power boosting capability for Guodian’s 15MW – 40MW coal powered facility to be located in China.

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

September 2013September 2013

Micure Therapeutics was established.

The company develops drugs and diagnostics tools for the treatment of depression and ALS. The technology was developed by Profs. Alon Chen and Eran Hornstein.

Micure Therapeutics was established.

The company develops drugs and diagnostics tools for the treatment of depression and ALS. The technology was developed by Profs. Alon Chen and Eran Hornstein.

Brainsway Gets FDA Approval Of IDE For Multi-Center Smoking Cessation Study 12

JERUSALEM, Sept. 11, 2013-Brainsway Ltd. (BRIN.TA) is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved an IDE (“Investigational Device Exemption”) that allows the Company to begin implementing a double-blind, multi-center study to assess the efficacy of the its Deep TMS device in inducing smoking cessation using a specialized coil developed for this purpose.

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

October 2013

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

Yeda and Osage University Partners, a venture capital fund that invests exclusively in startups that are commercializing university research, signed a collaboration agreement.

Cont’d

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

November 2013November 2013

Jianghua Group (JH), leading Chinese environmental solution provider, took a license to two technologies for treating contaminated water, developed by Prof. Brain Berkowitz.

Jianghua Group (JH), leading Chinese environmental solution provider, took a license to two technologies for treating contaminated water, developed by Prof. Brain Berkowitz. SynVaccine was established in the Rad Biomed incubator.The company develops a new safe and effective synthetic vaccines, based on the work of Prof. Ehud Shapira. Merck Serono and Kadimastem Sign Memorandum of Understanding (MOU) on Drug Screening and Discovery for Neurodegenerative Diseases.November 4. 2013 (Nes Ziona. Israel and Darmstadt. Germany) Merck Serono, a leading global pharmaceutical company, and Kadimastem, a developer of human pluripotent stem cell-based drug screening and therapeutic solutions, announced today the digning of an MOU aimed at advancing the two companies’ current stem cell-based drug screening collaboration which was initiated in April 2012.

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

Cont’d Cont’d

Yeda and BASF will collaborate in the development of novel materials and catalytic processes.

Yeda and BASF will collaborate in the development of novel materials and catalytic processes.

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

December 2013December 2013

Merck Millipore and Yeda sign a nonexclusive agreementfor the development marketing and sale of a novel kit for the creation of novel naïve stem cells, developed by Prof. Jacob Hanna.

Merck Millipore and Yeda sign a nonexclusive agreementfor the development marketing and sale of a novel kit for the creation of novel naïve stem cells, developed by Prof. Jacob Hanna.

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

January 2014

Merck Serono started collaboration with Prof. Idit Shahr for the research and development of new therapies for the treatment of Lukmia.

XTL Bio receives a license to develop a peptide, invited byProf. Edna Mozes, for the treatment of Lupus.

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

February 2014February 2014

Raptor Announces Clinical Results With RP103 in Huntington’s Disease 2/3 Trial

18 Month Clinical Results Showed Significantly Slower Progression of Total Motor Score in RP103 Treated Patients Without Tetrabenazine.

NOVATO, Calif., Feb.20,2014 (GLOBE NEWSWIRE) Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced top line results from a planned 18 month analysis of an ongoing 3 year Phase 2/3 clinical trail of RP103 (delayed-relese cysteamine) for the potential treatment of Huntington’s disease (HD) in collaboration with the Centre Hospiaier Universitaire d’Angers (CHU d’Angers ). A total of 96 patients with HD

Yeda and Merck Group (chemistry) announced 2 collaborations relating to research and development of novel chemical compounds.

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

Cont’d.Cont’d.

CO2 To Fuel Technology - Stage 2 - Efficiency Proven Mar. 12, 2014

NCF stage 2 testing further proves its technology, increasing dissociation rate of CO2 to 800 times original laboratory tests, a fourfold increase from Stage 1 testing announced in January | NCF continuous tests now running for over 100hrs, proving technology stability | NCF currently converting ~15kg CO2 into ~10kg of CO and 5kg oxygen (O2) per day

CO2 To Fuel Technology - Stage 2 - Efficiency Proven Mar. 12, 2014

NCF stage 2 testing further proves its technology, increasing dissociation rate of CO2 to 800 times original laboratory tests, a fourfold increase from Stage 1 testing announced in January | NCF continuous tests now running for over 100hrs, proving technology stability | NCF currently converting ~15kg CO2 into ~10kg of CO and 5kg oxygen (O2) per day

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

April 2014April 2014

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

May 2014May 2014

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

www. YedaRnD. c o mT h a n k y o u